Clinical trial
The Plenaxis® Experience Study
NCT00103623 · PRAECIS Pharmaceuticals Inc., Industry · Suspended
Key facts
| NCT number | NCT00103623 |
|---|---|
| Title | The Plenaxis® Experience Study |
| Official title | Incidence of Immediate Onset Systemic Allergic Reactions in Patients Treated With Plenaxis® |
| Lead sponsor | PRAECIS Pharmaceuticals Inc., Industry |
| Status | Suspended |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Plenaxis |
| Enrollment | 2,000 |
| Start date | Jun 1, 2004 |
| Completion | Dec 1, 2008 |
| First posted | Feb 14, 2005 |
| Last update posted | Sep 19, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: